Hi D***n, I hope you’re doing well. I’m J***e, an HR recruiter at StrategyBrain currently partnering with B***e T***s. I came across your profile and was really impressed by the innovative partnerships you’ve led at A***n,especially your success in structuring multi-target collaborations across RNA, machine-learning, and tolerance-induction programs. B***e is now looking for a Vice President of Strategic Partnerships and Business Development to shape global alliance strategy, lead high-stakes negotiations, and build a best-in-class team. Given your track record, I think you could be a great fit. Would you be open to a brief chat to explore this opportunity further? I’d love to share more about the role and learn about your career goals. Looking forward to hearing from you! Best regards, J***e HR Recruiter, StrategyBrain for B***e T***s

Hi D***n, Great to hear you’re interested. I’d be happy to walk you through the VP, Strategic Partnerships & Business Development role at B***e. Would a 20,30-minute call on Wednesday, May 1st at 10:00 AM PT or Thursday, May 2nd at 2:00 PM PT work for you? If not, feel free to suggest another slot. To give you a bit more context ahead of our chat: • Company & Mission: B***e T***s is a 250-person biotech pioneering immunotherapies and AI-powered discovery platforms. We pride ourselves on close R&D,commercial integration to accelerate breakthrough therapies. • Role Impact: As VP, you’ll define and execute global BD strategies, secure high-value collaborations in small molecules, biologics and AI discovery, and lead negotiations end-to-end. You’ll also partner with legal, regulatory, R&D and commercial teams to ensure seamless deal execution and drive joint value creation. • Leadership & Growth: You’ll build and mentor a team of BD professionals, establish performance metrics and shape our strategic alliance portfolio. This position reports directly to the Chief Business Officer and offers significant influence on company direction. • Resources & Rewards: We offer strong cross-functional support, a competitive compensation package plus equity incentives, and clear pathways for professional growth. Does this overview resonate with your background and aspirations? Let me know which time works best or if you have any questions before our call. Looking forward to connecting, J***e

Hi D***n, Great to hear May 1st at 10:00 AM PT works for you,I’ll send a calendar invite shortly. As for your questions: 1. Current BD team size • We’re a lean group of five professionals: three BD Directors handling origination and negotiations, plus two Alliance Managers focused on deal execution and partner stewardship. 2. Top strategic priorities for the VP in months 1,6 • Define and roll out a global BD strategy, zeroing in on our immunotherapy programs and AI-driven discovery platform. • Identify and execute 2,3 high-value partnerships with biotech/tech collaborators, shepherding deals from term sheet through signature. • Build and mentor your direct reports,establish clear performance metrics, refine our cross-functional handoff processes (legal, R&D, commercial), and foster a culture of collaboration. • Streamline due diligence and deal-structuring workflows to accelerate time to close without sacrificing rigor. • Lay the groundwork for an expanded team in H2, aligning headcount and skill sets to our pipeline goals. Looking forward to walking you through these in more detail next week. Talk soon! Best, J***e HR Recruiter, StrategyBrain for B***e T***s

Hi D***n, Great questions,happy to provide more color ahead of our call: 1. Immunotherapy focus • We’re advancing a mix of modalities: bispecific antibodies are our lead programs (both oncology and immuno‐oncology), we have an ADC in late preclinical/IND-enabling studies, and we’re launching an allogeneic cell-therapy platform in collaboration with a strategic academic partner. 2. AI-driven discovery platform • Our in-house team has built proprietary ML models for target identification and small-molecule lead optimization. We’ve also partnered with a well-established AI biotech firm to co-develop de-novo molecule design workflows and are integrating cloud-based bioinformatics suites for rapid hit triaging. 3. H2 team expansion • We’ll be looking to add: , Two Senior BD Managers with deep experience in cell-therapy or ADC partnerships , A Strategic Alliance Manager dedicated to our AI collaborations , A Deal/Financial Analyst to streamline modeling and diligence for complex, cross-modal transactions Looking forward to diving deeper on May 1st at 10:00 AM PT. Let me know if any other details would be helpful beforehand. Best, J***e

Hi D***n, Great questions,happy to share more detail: 1. Allogeneic platform & IND timeline • We’re partnering with a top-tier academic immuno-oncology group under a confidentiality agreement; they bring deep expertise in allogeneic cell manufacturing. We kicked off process development last quarter and are targeting IND submission in late 2025, pending completion of preclinical safety and CMC milestones. 2. In-house ML model maturity • Our proprietary ML suite has been in production for over a year, powering both target identification and lead optimization. We routinely screen and triage a significant volume of virtual candidates per campaign, with hit-rate metrics that meet or exceed industry benchmarks. Continuous wet-lab feedback and retrospective validations help us refine predictive performance. 3. Early hurdles for new BD hires • Negotiating IP ownership and data-sharing terms for co-developed AI algorithms • Aligning cross-functional due diligence,especially CMC requirements for cell therapies and validation of ML outputs • Structuring balanced risk-share and milestone frameworks across biologics and digital assets Looking forward to diving deeper on our call May 1st at 10:00 AM PT. Let me know if there’s anything else you’d like ahead of time. Best regards, J***e

Hi D***n, Great questions,here’s a bit more color ahead of our call: 1. Allogeneic platform • We’re currently advancing a donor-derived primary cell platform, with a parallel iPSC-based program under evaluation for longer-term scalability. • Early process-development runs are hitting viability and expansion metrics in line with industry norms (high-80s % viability, mid-10^8 cell yields per batch) and continue to improve as we optimize bioreactor conditions. 2. ML suite throughput & hit rates • A typical campaign screens on the order of 10^5 to 10^6 virtual candidates, leveraging both our in-house models and partner algorithms. • We set initial in silico hit-rate thresholds in the low-single-digit percentages for progression to wet-lab triage, then see validation rates in line with best-in-class benchmarks once compounds reach biochemical assays. 3. Early AI IP negotiations • We’ve encountered the most pushback around data-sharing scope,partners want clarity on raw output access and downstream use,whereas carve-outs on algorithm ownership generally fall into place once milestone-based licensing terms are defined. If you’d like deeper technical detail, I can bring our CMC lead or ML director onto the call. Let me know if there’s anything else you’d like to cover before Wednesday. Looking forward to our conversation! Best, J***e

Hi D***n, Great questions,here’s a bit more detail ahead of our call: 1. Batch‐to‐batch variability • We enforce strict SOPs and raw‐material qualification, with QC at each step (viability, expansion kinetics, phenotype markers and functional potency assays) to ensure consistency in line with industry norms. Ongoing process analytics allow us to spot drifts early and implement corrective actions. 2. iPSC scale‐up roadmap • Our GMP‐grade master cell bank is under final qualification. We’re transferring the optimized differentiation and expansion process into our pilot GMP suite this quarter, with full GMP runs targeted by early 2025 to align with IND timelines. 3. ML retraining cadence & drift monitoring • We operate a continuous feedback loop,models are retrained quarterly (or following each significant wet‐lab campaign) using the latest assay data. We track standard metrics (ROC-AUC, precision/recall, calibration) and deploy drift detectors (e.g. population‐stability indices) to flag shifts in input distributions or predictive performance. If you’d like a deeper technical dive, I can loop in our CMC lead or ML Director on the call. Looking forward to exploring this and more on May 1st at 10:00 AM PT. Best, J***e